Actively Recruiting
FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)
Led by Centre Georges Francois Leclerc · Updated on 2023-10-17
38
Participants Needed
3
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hybrid positron emission tomography/computed tomography (PET/CT) has now become available to detect tumors in patients with multiple myeloma. The radioactive glucose 18F-fluorodeoxyglucose (FDG) is the most widely used tracer but findings suggest that PET/CT reveal more lesions when using FCH. In this study, FDG is compared with a more recent metabolic tracer, 18F-fluorocholine (FCH), for the detection of multiple myeloma lesions at time of initial extension assessment. The principal objective of this sudy is to compare the number of suspected hypermetabolic foci of myeloma detected by 18F-fluorocholine PET and by 18F-fluorodeoxyglucose PET during the initial extension assessment.
CONDITIONS
Official Title
FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with initial diagnosis of multiple myeloma has just been established
- Therapeutic indication and eligible for a HSC autograft (if the HSC autograft could not be performed, the patient will still be retained in the study)
- Status ECOG 0, 1 or 2
- Age 63 18 and < 75 years
- Effective contraception for women
- Informed consent signed
- Patient able to lie flat for 30 minutes
- Patient affiliated to a social security scheme
You will not qualify if you...
- Diagnosis of MGUS, indolent myeloma (smoldering myeloma), non-secreting myeloma, or recurrent myeloma
- Already under treatment for myeloma
- Not eligible for intensive treatment followed by a HSC autograft
- Presence of concomitant neoplasia
- History of hematological or solid neoplasia except basal cell carcinoma or adenocarcinoma in situ of uterine cervix
- History of sarcoidosis
- Uncontrolled diabetes
- Treatment with long-term corticosteroids
- Treatment with hematopoietic growth factors
- Patient in sepsis
- Claustrophobia
- Refusal of patient consent
- Pregnant or lactating woman
- Women of childbearing potential without effective contraception
- Person deprived of liberty or under guardianship
- Inability to follow medical follow-up due to geographic, social, or psychological reasons
- History of allergic reaction to 18F-fluorodeoxyglucose or 18F-fluorocholine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
CHU de Besançon
Besançon, France, 25000
Actively Recruiting
2
Centre Georges François Leclerc
Dijon, France, 21000
Actively Recruiting
3
CHU de Dijon
Dijon, France, 21000
Actively Recruiting
Research Team
E
Emilie REDERSTORFF
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here